FRG SOMATOMEDINS AND GROWTH HORMONE (GH) SECRETION IN ULLRICH-TURNER SYNDROME (UTS)
In recent time attempts are made to treat short stature in UTS with GH. What evidence exists for disturbance of the GH-somatomedin axis causing the growth disorder in UTS ? --In a total of 56 children and adolescents with UTS (45,X;N=45) the following parameters were measured in a cross-sectional manner: somatomedin activity (Sm; porc.cart.), Sm-C/IGF I (RIA), IGF 1 1 (RIA),-G H in response to: arginine, GRF(1-29)NH2, and 5.5 h of sleep (SrGH). --Normal levels of IGF 1 1 and to arginin and GRF were seen. S m was high before BA 1 0 yrs., normal later. Sm-C was normal before BA 1 0 yrs, low-normal later. In relation to height Sm-C levels are higher than normal before BA 1 0 yrs.. SrGH was declining with age not showing the normal puberty-associated rise. Low doses of estrogens (EE, 100 ng/kg d) a n d o x a n d r o l o n e (150 ug/kg d)
induced a rise in Sm-C. --The data provide no evidence for the existence of a genuine disorder of the GI-l-somatomedin axis. They rather point to a partial resistance to this system, at least before the effects of gonadal dysgenesis emerge. Thus, only supra-substitution doses of G H should be effective in improving growth in UTS. Physiological growth hormone (GH) s e c r e t i o n has been assessed by i n t e r m i t t e n t 20 minute sampling over 24 hours i n 31 Turner Syndrome (TS) p a t i e n t s aged 4 . 3 t o 12.4 years. Computer pulse analysis was performed (Merrim & Wachter) and r e s u l t s expressed a s t h e sum of Gtl pulse amplitudes (SPA). I n 22 p r o f i l e s the Gll pulse frequency was comparable t o t h a t seen in normal s h o r t c h i l d r e n ; i n 9, the GI1 pulsc frequency !ins unusually f a s t (n=7) o r showed a s i n g l e high pulse (n=2). P a t t e r n s auch a s these a r e a s s o c i a t e d with low h e i g h t v e l o c i t y in s h o r t c h i l d r e n but the growth of these 9 TS p a t i e n t s was not slower than t h a t OF the 22. I n the 'normal' p r o f i l e s t h e r e was a d e c l i n e i n SPA with age; t h i s c o n t r a s t e d with I G F -1 concentrations w h~c h r o s e with agc. The r e l a t i o n s h i p between h e i g h t v e l o c i t y and GI1 SPA demonstrated i n s h o r t c h i l d r e n (ESPE, 1986) was absent ~n TS p a t i e n t s .
Oxandralone given i n a dose of 0.9-l.8mg/mz/24 hours t o 12 p a t i e n t s .
Height v e l o c i t y increased; GI1 p r o f i l e s did not change but plasma IGF-1 c o n c e n t r a t i o n s rose.
We conclude 1) t h a t end organ i n s e n s i t i v i t y probably plays an important p a r t i n the growth f a i l u r e of Turner Syndrome and 2) t h a t the growth promoting e f f e c t s of oxandrolona a r e not mediated by increased GH s e c r e t i o n .
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GROWTH IN THE NOONAN SYNDROME (NS)
The Noonan S. diplays a variety of symptoms similar to the Ullrich-Turner S. (UTS). Main differences to the UTS are (besides some variance in the pattern of dysmorphic symptoms) frequent mental impairments, congenital pulmonary stenoses, absence of gonadal dysgenesis, normal karyotype and occurrence in both genders. Although N S is reported to be more frequent than UTS (1:1000 vs. 1:5000 births) comparatively little is known about its auxology. -Auxolgical data of 80 (45m/35f) cases were analysed and standards for height were derived. N S shows the following auxological characteristics: normal size at birth, -growth at 3rd perc. until puberty, -males are always relatively smaller than females (ca. 1 SO), -puberty is retarded by ca. two years, -height/weight ratio is normal, -B A is retarded, -males (N=12) approach 159.4 (+-6.9) cm, females (N=22) 150.2 (+-9.5) cm. -Female growth differs from UTS also before puberty.
--The data may serve for councelling and may guide during treatment trials with growth promoting pharmaca Centro di Endocrinologia Infantile e dell'Adolescenza, 134 Clinlca Pediatrica 3a,UniversltB degli Studl, lstlt.
Scientlfico I I San Raffaele, Milano,Italia. BONE MINERAL CONTENT IN TURNER'S SYNDROME.
Bone mineral content of subjects with Turner's syndrome has been found smaller than predicted by age and sex. Bone mineral content related to bone width (BMC/BW) of 19 patients with Turner's syndrome not yet receiving estrogen replacement therapy (mean age: 11 yrs;range: 6-15 yrs) and of 22 patients receiving exogenous estrogens (mean age: 17 yrs 7/12; range: 11 yrs 8/12-28 yrs 4/12) was evaluated by single photon absorptiometry of distal forearm. In both groups BMC/BW was significantly reduced (p<0.025 and p<0.0001 respcctivc1y)when compared with normal subjects. Seven patients with Turner's syndrorne,ln whom estrogen replacement therapy had begun at a chronological age less than 14 yrs,have been examined longitudinally to evaluate the role of estrogens in bone mineralization. Thc average increase In UMC/BW was 11% and 7% at G and 18 months respectively,after the beginning of therapy. However,thc UMC/BW values remalned below normal. Our data conflrm a deficit in bone mass In patients wlth Turner' s syndrome; bone deminerallzation 1s present also at prepubertal age. In our experience,precocious estrogen treatment (11-14 yrs) can improve bone mass in patients with Turner's syndrome.
L.Landi*, R.BergamaschiX, E . C a c c i a r i .
Dep~rtment of P e d i a t r i c s . S.Orsola Hospital, University of
Bologna. I t a l y
EFFECT OF ESTROGES-PROGESTOGEN T R E A T M C N T ON CARBOlIYORATE TOLERAEICE
I N TURNER'S SYNDROME Glucose tolerance was evaluated by means of an O G T T in 16 g i r l s with Turner's syndrome submitted to estrogen-progestogen treatment (10 s u b j e c t s 4 5 , X , I X-mosaic and 5 X s t r u c t u r a l a b n o r m a l i t i e s ) . OGTT u a s performed before treatment, on treatmcnt a f t e r Lhe f i r s t 3 months ( 1 s t c o n t r o l ) and a f t e r various cycles of 3 months each (2nd c o n t r o l ) , and a f t e r therapy uithdraual f o r 3 months a f t e r l a s t cycle. On treatment: s i g n i f i c a n t l y higher blood glucose values than those of values uere lower ( p < 0.05 a t 180 mins) than those observed during treatment and no longer showed s i g n i f i c a n t d i f f e r e n c e s compared to pretreatment values. These data show estrogen-progestogen replacement therapy induces an increase in i n s u l i n requirements which however does not prevent an increase I n blood glucose values. This phenomenon can be reversed a f t e r hormone replacement treatment has been suspended. I n conclusion although c a r e should be exercised whrn Turner's p a t i e n t s receive s t e r o i d replacement therapy, b r i e f treatment withdrawal seems s u f f i c i e n t to induce a r e c o v e r y o f glucose tolerance. We have prospectively evaluated the effect of a short term high dose testosterone therapy on height and BA In tall boys. BA was assessed according to the Greulich-Pyle method. Adult height was predicted with the tables of Bayley-Pinneau. Treatment consisted of intramuscular injections of 500 mg testosterone oenanthate every 2 weeks for 6 months. Height and BA were determined beiore, at the end of and 3 , 6 and 12 months after therapy. 34 boys have been followed for at least 6 months after therapy.
A9AIACA accelerated by 2.46 + 0.82 years (mean + SO) during therapy and by 2.99 + 1.14, 2.23 t 0.78 and 1.58 + 0.46 years 3 , 6 and 12 months thereafter, thus demonstrating, that BA-acceleration persists for several months after treatment.
12 boys were measured 2.50 + 0.34 years after therapy. Their initial bone age was 14.02 + 0.52 years with a predicted height of 204.99 + 4.25 cm. At the end of therapy height was 193.61 + 5.59 cm and bone age 15.67 + 0.58 years. Height at the time of the last evaluation was 197.38 + 4.11 cm, which is 7.61 + 5.6 cm less than predicted. The reduction of 50.26 + 14.55 % is-similar to the one observed in 115 boys treated for 14.25 + 4.14 months with the same therapeutic reqimen. We conclude, that with the persistent acceleration of 8A after treatment only 6 months of hlgh dose testosterone therapy are needed to effectively reduce height in boys with tall stature.
